What impacted Regeneron's gross profit margins recently?

Regeneron's gross profit margins were impacted by several factors recently:

1. **Increased Cost of Sales**: The cost of goods sold for Regeneron increased to $565.4 million. This increase in cost directly impacts the gross profit margin, as it represents the expenses incurred in the production and sale of the company's products.

|code|Ticker|Name|Date|Gross Profit Margin|Cost of Goods Sold|Total Revenue|market_code|
|---|---|---|---|---|---|---|---|
|REGN|REGN.O|Regeneron|2024 Q1|89.5347|4.338E8|3.145E9|185|
|REGN|REGN.O|Regeneron|2024 Q2|89.2964|4.802E8|3.5471E9|185|
|REGN|REGN.O|Regeneron|2024 Q3|89.3869|4.911E8|3.7207E9|185|
|REGN|REGN.O|Regeneron|2024 Q4|89.3658|5.654E8|3.7892E9|185|

2. **Lower Net Selling Price**: There was a lower net selling price for Eylea HD and Eylea, which adversely affected the net product sales in the fourth quarter and full year 2024 compared to the same periods of 2023. This decrease in selling price negatively impacted the gross profit margin, as it reduces the revenue generated from each unit sold.
3. **Increased Collaboration Costs**: Collaboration revenues from Sanofi for Dupixent were lower than expected, missing the Zacks Consensus Estimate. This could indicate that the costs associated with collaboration projects are higher than anticipated, which would impact the gross profit margin.
4. **Legal Challenges and Investigations**: Regeneron is facing investigations regarding alleged violations of federal securities laws and the False Claims Act. These legal challenges could lead to increased expenses, including legal fees and potential penalties, which would impact the gross profit margin.

In summary, Regeneron's gross profit margins were impacted by increased cost of sales, lower net selling prices, increased collaboration costs, and legal challenges. These factors combined to affect the company's profitability and financial performance.